NYSE:NVOPharmaceuticals
Novo Nordisk Balances Oral Wegovy Launch With Legal Fight On Compounds
Novo Nordisk (NYSE:NVO) has taken legal action against Hims & Hers over compounded versions of its Wegovy pill that do not have individual FDA approval.
The FDA has moved to restrict unapproved compounded GLP-1 products, including versions referencing Wegovy, citing safety and quality concerns.
Novo Nordisk has received FDA approval for an oral Wegovy pill for obesity and has started its commercial launch in the U.S.
Novo Nordisk, best known for its obesity and diabetes treatments, now has...